Bariatric surgery decreases the risk of uterine malignancy

A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placeboasfirst-line treatment formetastatic uterine leiomyosarcoma (uLMS): A Gynecologic Oncology Group study M.L. Hensley, A. Miller, D.M. O'Malley, R.S. Mannel, K. Behbakht, J.N. Bakkum-Gamez, H. Michael. Memorial Sloan Kettering Cancer Center, New York, NY, USA, Gynecologic Oncology Group, Buffalo, NY, USA, The Ohio State University, Columbus, OH, USA, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, University of Colorado Denver, Aurora, CO, USA, Mayo Clinic, Rochester, MN, USA, Indiana University School of Medicine, Indianapolis, IN, USA.